Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 21 (7) , 477-496
- https://doi.org/10.2165/00019053-200321070-00003
Abstract
Patients who have undergone orthopaedic surgery represent a high-risk group for venous thromboembolism (VTE). Despite the routine prophylactic use of antithrombotic agents, patients still experience...Keywords
This publication has 133 references indexed in Scilit:
- Developing Guidance for Budget Impact AnalysisPharmacoEconomics, 2001
- Late occurring clinical deep vein thrombosis in joint-operated patientsActa Orthopaedica, 2000
- The Role of Cost-Consequence Analysis in Healthcare Decision-MakingPharmacoEconomics, 1998
- Economic Evaluation of Desirudin vs Heparin in Deep Vein Thrombosis Prevention after Hip Replacement SurgeryPharmacoEconomics, 1998
- Cost Effectiveness of a Low-Molecular-Weight Heparin in Prolonged Prophylaxis Against Deep Vein Thrombosis After Total Hip ReplacementPharmacoEconomics, 1998
- EnoxaparinPharmacoEconomics, 1996
- Thromboprophylaxis with Low Molecular Weight Heparin after Major Orthopaedic Surgery is Cost EffectiveDrugs, 1996
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1982
- Adjusted Subcutaneous Heparin versus Warfarin Sodium in the Long-Term Treatment of Venous ThrombosisNew England Journal of Medicine, 1982